FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GRK5-SUMF1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GRK5-SUMF1
FusionPDB ID: 34889
FusionGDB2.0 ID: 34889
HgeneTgene
Gene symbol

GRK5

SUMF1

Gene ID

2869

285362

Gene nameG protein-coupled receptor kinase 5sulfatase modifying factor 1
SynonymsFP2025|GPRK5AAPA3037|FGE|UNQ3037
Cytomap

10q26.11

3p26.1

Type of geneprotein-codingprotein-coding
DescriptionG protein-coupled receptor kinase 5g protein-coupled receptor kinase GRK5formylglycine-generating enzymeC-alpha-formylglycine-generating enzyme 1FGly-generating enzyme
Modification date2020031320200313
UniProtAcc

P34947

Main function of 5'-partner protein: FUNCTION: Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro). {ECO:0000269|PubMed:19661922, ECO:0000269|PubMed:19801552, ECO:0000269|PubMed:20038610, ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:21728385}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000369108, ENST00000392870, 
ENST00000473264, 
ENST00000272902, 
ENST00000383843, ENST00000405420, 
ENST00000458465, ENST00000470751, 
ENST00000534863, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score8 X 8 X 4=2567 X 6 X 4=168
# samples 97
** MAII scorelog2(9/256*10)=-1.50814690367033
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/168*10)=-1.26303440583379
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GRK5 [Title/Abstract] AND SUMF1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GRK5 [Title/Abstract] AND SUMF1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GRK5(121191039)-SUMF1(4110429), # samples:2
Anticipated loss of major functional domain due to fusion event.GRK5-SUMF1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GRK5-SUMF1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GRK5-SUMF1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
GRK5-SUMF1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneGRK5

GO:0007217

tachykinin receptor signaling pathway

17986524

HgeneGRK5

GO:0043066

negative regulation of apoptotic process

20124405

HgeneGRK5

GO:0046777

protein autophosphorylation

14976207

TgeneSUMF1

GO:0018158

protein oxidation

21224894|25931126

TgeneSUMF1

GO:0043687

post-translational protein modification

21224894|25931126



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:121191039/chr3:4110429)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GRK5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SUMF1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000392870GRK5chr10121191039+ENST00000534863SUMF1chr34110429-133410672091333375
ENST00000369108GRK5chr10121191039+ENST00000534863SUMF1chr34110429-92966262928289

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000392870ENST00000534863GRK5chr10121191039+SUMF1chr34110429-0.0042580230.9957419
ENST00000369108ENST00000534863GRK5chr10121191039+SUMF1chr34110429-0.0048686720.9951314

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GRK5-SUMF1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GRK5chr10121191039SUMF1chr341104291067284LNEKQILEKVNSQFVSQEYYDPYFQD
GRK5chr10121191039SUMF1chr34110429662198LNEKQILEKVNSQFVSQEYYDPYFQD

Top

Potential FusionNeoAntigen Information of GRK5-SUMF1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GRK5-SUMF1_121191039_4110429.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:01SQFVSQEY0.99970.75551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:01LEKVNSQF0.99770.9595614
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:25SQFVSQEY0.99580.81351119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:02SQFVSQEY0.98430.84511119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:03SQFVSQEY0.94210.57171119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:18SQFVSQEY0.94090.50071119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:01SQFVSQEY0.88560.7331119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:01SQFVSQEYY0.99970.74561120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:25SQFVSQEYY0.99090.78341120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:02NSQFVSQEY0.98830.78051019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:02SQFVSQEYY0.98210.81541120
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:08NSQFVSQEY0.97980.64471019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:01ILEKVNSQF0.96990.8798514
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:01NSQFVSQEY0.95720.6981019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:25ILEKVNSQF0.92880.9266514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:02ILEKVNSQF0.88350.9303514
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:01SQFVSQEYY0.78370.76731120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:03SQFVSQEYY0.73080.50591120
GRK5-SUMF1chr10121191039chr34110429662HLA-A32:13ILEKVNSQF0.70610.9109514
GRK5-SUMF1chr10121191039chr34110429662HLA-B13:01SQFVSQEYY0.55570.8381120
GRK5-SUMF1chr10121191039chr34110429662HLA-A32:13SQFVSQEYY0.13010.72931120
GRK5-SUMF1chr10121191039chr34110429662HLA-B13:01ILEKVNSQF0.05670.9341514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:01KQILEKVNSQF10.7808314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:01KVNSQFVSQEY0.99990.8166819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:25KVNSQFVSQEY0.99960.8495819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:03KQILEKVNSQF0.99150.6241314
GRK5-SUMF1chr10121191039chr34110429662HLA-B13:01KQILEKVNSQF0.97060.9367314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:04SQFVSQEY0.99620.77181119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:21SQFVSQEY0.98760.78871119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:05SQFVSQEY0.97870.71551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:31SQFVSQEY0.94280.72571119
GRK5-SUMF1chr10121191039chr34110429662HLA-C04:10ILEKVNSQF0.99830.7947514
GRK5-SUMF1chr10121191039chr34110429662HLA-C04:07ILEKVNSQF0.99830.8044514
GRK5-SUMF1chr10121191039chr34110429662HLA-C05:09ILEKVNSQF0.99810.9261514
GRK5-SUMF1chr10121191039chr34110429662HLA-C08:15ILEKVNSQF0.99660.9749514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:21NSQFVSQEY0.9870.73951019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:21SQFVSQEYY0.9810.7631120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:05NSQFVSQEY0.97580.62821019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:05SQFVSQEYY0.95940.71641120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:31NSQFVSQEY0.95860.64081019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:31SQFVSQEYY0.92810.72881120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:04SQFVSQEYY0.89260.76181120
GRK5-SUMF1chr10121191039chr34110429662HLA-C15:04NSQFVSQEY0.74650.73331019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:05ILEKVNSQF0.63350.9174514
GRK5-SUMF1chr10121191039chr34110429662HLA-C04:06ILEKVNSQF0.61770.8423514
GRK5-SUMF1chr10121191039chr34110429662HLA-C03:14SQFVSQEYY0.57070.95131120
GRK5-SUMF1chr10121191039chr34110429662HLA-C03:14NSQFVSQEY0.33860.92531019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:07KQILEKVNSQF0.99980.6585314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:07KVNSQFVSQEY0.99970.5436819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:05KQILEKVNSQF0.96640.8516314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:34SQFVSQEY0.99970.75551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:27SQFVSQEY0.99970.78031119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:33SQFVSQEY0.99970.75551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:125SQFVSQEY0.99970.75551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135SQFVSQEY0.99970.76041119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:50SQFVSQEY0.99950.75841119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:24SQFVSQEY0.99930.73411119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:35SQFVSQEY0.99920.72751119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:53SQFVSQEY0.99860.69241119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:12SQFVSQEY0.99830.71431119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:08LEKVNSQF0.99780.8968614
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:05LEKVNSQF0.99770.9595614
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:06LEKVNSQF0.99740.9661614
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:39SQFVSQEY0.9960.67711119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:54SQFVSQEY0.99530.6561119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:53LEKVNSQF0.9950.879614
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:03LEKVNSQF0.99330.9551614
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:11LEKVNSQF0.98490.9285614
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:20SQFVSQEY0.97830.82051119
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28SQFVSQEY0.97060.83811119
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:20SQFVSQEY0.93670.84731119
GRK5-SUMF1chr10121191039chr34110429662HLA-C12:02SQFVSQEY0.92960.92611119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:11SQFVSQEY0.92610.71761119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:04SQFVSQEY0.91140.76431119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:06SQFVSQEY0.9060.72551119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:07SQFVSQEY0.89710.67121119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:05SQFVSQEY0.88560.7331119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:08SQFVSQEY0.88290.64031119
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:03SQFVSQEY0.86520.71281119
GRK5-SUMF1chr10121191039chr34110429662HLA-B48:02SQFVSQEY0.79340.80381119
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:125SQFVSQEYY0.99970.74561120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:33SQFVSQEYY0.99970.74561120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:27SQFVSQEYY0.99970.75261120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:34SQFVSQEYY0.99970.74561120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135SQFVSQEYY0.99960.74241120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:50SQFVSQEYY0.99950.73671120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:24SQFVSQEYY0.99860.68961120
GRK5-SUMF1chr10121191039chr34110429662HLA-C04:03ILEKVNSQF0.99830.8264514
GRK5-SUMF1chr10121191039chr34110429662HLA-C04:01ILEKVNSQF0.99830.8044514
GRK5-SUMF1chr10121191039chr34110429662HLA-C05:01ILEKVNSQF0.99810.9261514
GRK5-SUMF1chr10121191039chr34110429662HLA-C18:01ILEKVNSQF0.99760.7965514
GRK5-SUMF1chr10121191039chr34110429662HLA-C08:02ILEKVNSQF0.99660.9749514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:12SQFVSQEYY0.99650.71091120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:53SQFVSQEYY0.99510.67821120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:35SQFVSQEYY0.99460.70491120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:39SQFVSQEYY0.99140.61991120
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:11NSQFVSQEY0.9850.72221019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:11NSQFVSQEY0.98090.59881019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:08NSQFVSQEY0.97790.59451019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:50ILEKVNSQF0.97730.9161514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:20NSQFVSQEY0.97690.7421019
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:43NSQFVSQEY0.97120.58931019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:34ILEKVNSQF0.96990.8798514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:33ILEKVNSQF0.96990.8798514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:125ILEKVNSQF0.96990.8798514
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28NSQFVSQEY0.96890.76741019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135ILEKVNSQF0.96760.8773514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:12ILEKVNSQF0.96620.8884514
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:23NSQFVSQEY0.95950.71871019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:20SQFVSQEYY0.95850.82371120
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:20NSQFVSQEY0.9580.79321019
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:77NSQFVSQEY0.95720.6981019
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28SQFVSQEYY0.9420.83071120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:24ILEKVNSQF0.93020.9132514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:39ILEKVNSQF0.930.772514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:54SQFVSQEYY0.92460.64331120
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:11SQFVSQEYY0.92220.7411120
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:20SQFVSQEYY0.90850.84491120
GRK5-SUMF1chr10121191039chr34110429662HLA-C03:02NSQFVSQEY0.90610.9051019
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:24NSQFVSQEY0.86880.68671019
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:04SQFVSQEYY0.86030.79491120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:13SQFVSQEYY0.8260.50051120
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:07SQFVSQEYY0.81890.691120
GRK5-SUMF1chr10121191039chr34110429662HLA-A30:01KVNSQFVSQ0.81130.9635817
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:08SQFVSQEYY0.80620.63931120
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:05SQFVSQEYY0.78370.76731120
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:13ILEKVNSQF0.74770.5465514
GRK5-SUMF1chr10121191039chr34110429662HLA-C15:09NSQFVSQEY0.74650.73331019
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:06SQFVSQEYY0.73860.761120
GRK5-SUMF1chr10121191039chr34110429662HLA-C12:02NSQFVSQEY0.66870.90291019
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:20ILEKVNSQF0.65040.9566514
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:73SQFVSQEYY0.60950.71891120
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28ILEKVNSQF0.60440.9544514
GRK5-SUMF1chr10121191039chr34110429662HLA-B48:02SQFVSQEYY0.6030.80141120
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:04NSQFVSQEY0.55530.69261019
GRK5-SUMF1chr10121191039chr34110429662HLA-C16:04NSQFVSQEY0.35710.95081019
GRK5-SUMF1chr10121191039chr34110429662HLA-B18:07NSQFVSQEY0.35220.611019
GRK5-SUMF1chr10121191039chr34110429662HLA-C12:03NSQFVSQEY0.34210.94641019
GRK5-SUMF1chr10121191039chr34110429662HLA-C12:02SQFVSQEYY0.23850.90641120
GRK5-SUMF1chr10121191039chr34110429662HLA-C02:02SQFVSQEYY0.20540.93781120
GRK5-SUMF1chr10121191039chr34110429662HLA-C02:10SQFVSQEYY0.20540.93781120
GRK5-SUMF1chr10121191039chr34110429662HLA-C16:02NSQFVSQEY0.09960.95381019
GRK5-SUMF1chr10121191039chr34110429662HLA-C16:01NSQFVSQEY0.0660.93471019
GRK5-SUMF1chr10121191039chr34110429662HLA-C02:10NSQFVSQEY0.02670.92061019
GRK5-SUMF1chr10121191039chr34110429662HLA-C02:02NSQFVSQEY0.02670.92061019
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28NSQFVSQEYY0.94890.67391020
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:20NSQFVSQEYY0.93030.69831020
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135KQILEKVNSQF10.8115314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:27KQILEKVNSQF10.8072314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:33KQILEKVNSQF10.7808314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:34KQILEKVNSQF10.7808314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:125KQILEKVNSQF10.7808314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:50KVNSQFVSQEY0.99990.8806819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:125KVNSQFVSQEY0.99990.8166819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:33KVNSQFVSQEY0.99990.8166819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:50KQILEKVNSQF0.99990.8682314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:53KQILEKVNSQF0.99990.7288314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:24KQILEKVNSQF0.99990.875314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135KVNSQFVSQEY0.99990.8171819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:34KVNSQFVSQEY0.99990.8166819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:35KVNSQFVSQEY0.99980.768819
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:35KQILEKVNSQF0.99960.7671314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:68KQILEKVNSQF0.99920.592314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:54KQILEKVNSQF0.99840.7186314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:135VNSQFVSQEYY0.99730.6038920
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28VNSQFVSQEYY0.98080.7237920
GRK5-SUMF1chr10121191039chr34110429662HLA-B48:02KQILEKVNSQF0.97910.9087314
GRK5-SUMF1chr10121191039chr34110429662HLA-B15:20KQILEKVNSQF0.96740.9031314
GRK5-SUMF1chr10121191039chr34110429662HLA-B35:28KQILEKVNSQF0.95570.9128314

Top

Potential FusionNeoAntigen Information of GRK5-SUMF1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GRK5-SUMF1_121191039_4110429.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GRK5-SUMF1chr10121191039chr34110429662DRB1-0701KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0703KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0705KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0707KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0708KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0709KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0712KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0713KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0714KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0715KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0716KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0717KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-0719KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-1615KQILEKVNSQFVSQE318
GRK5-SUMF1chr10121191039chr34110429662DRB1-1615EKQILEKVNSQFVSQ217

Top

Fusion breakpoint peptide structures of GRK5-SUMF1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4905LEKVNSQFVSQEYYGRK5SUMF1chr10121191039chr34110429662

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GRK5-SUMF1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4905LEKVNSQFVSQEYY-7.1392-7.251
HLA-B14:023BVN4905LEKVNSQFVSQEYY-4.27075-5.31385
HLA-B52:013W394905LEKVNSQFVSQEYY-7.16965-7.28145
HLA-B52:013W394905LEKVNSQFVSQEYY-4.14817-5.19127
HLA-A11:014UQ24905LEKVNSQFVSQEYY-8.05119-9.09429
HLA-A11:014UQ24905LEKVNSQFVSQEYY-4.2696-4.3814
HLA-A24:025HGA4905LEKVNSQFVSQEYY-9.2803-9.3921
HLA-A24:025HGA4905LEKVNSQFVSQEYY-8.62855-9.67165
HLA-B44:053DX84905LEKVNSQFVSQEYY-6.35744-6.46924
HLA-B44:053DX84905LEKVNSQFVSQEYY-4.81846-5.86156
HLA-A02:016TDR4905LEKVNSQFVSQEYY-3.81801-4.86111

Top

Vaccine Design for the FusionNeoAntigens of GRK5-SUMF1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GRK5-SUMF1chr10121191039chr341104291019NSQFVSQEYCAGTTTGTGTCCCAAGAGTACTATGAT
GRK5-SUMF1chr10121191039chr341104291020NSQFVSQEYYCAGTTTGTGTCCCAAGAGTACTATGATCCC
GRK5-SUMF1chr10121191039chr341104291119SQFVSQEYTTTGTGTCCCAAGAGTACTATGAT
GRK5-SUMF1chr10121191039chr341104291120SQFVSQEYYTTTGTGTCCCAAGAGTACTATGATCCC
GRK5-SUMF1chr10121191039chr34110429314KQILEKVNSQFATCCTCGAGAAGGTCAACAGTCAGTTTGTGTCC
GRK5-SUMF1chr10121191039chr34110429514ILEKVNSQFGAGAAGGTCAACAGTCAGTTTGTGTCC
GRK5-SUMF1chr10121191039chr34110429614LEKVNSQFAAGGTCAACAGTCAGTTTGTGTCC
GRK5-SUMF1chr10121191039chr34110429817KVNSQFVSQAACAGTCAGTTTGTGTCCCAAGAGTAC
GRK5-SUMF1chr10121191039chr34110429819KVNSQFVSQEYAACAGTCAGTTTGTGTCCCAAGAGTACTATGAT
GRK5-SUMF1chr10121191039chr34110429920VNSQFVSQEYYAGTCAGTTTGTGTCCCAAGAGTACTATGATCCC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GRK5-SUMF1chr10121191039chr34110429217EKQILEKVNSQFVSQCAGATCCTCGAGAAGGTCAACAGTCAGTTTGTGTCCCAAGAGTAC
GRK5-SUMF1chr10121191039chr34110429318KQILEKVNSQFVSQEATCCTCGAGAAGGTCAACAGTCAGTTTGTGTCCCAAGAGTACTAT

Top

Information of the samples that have these potential fusion neoantigens of GRK5-SUMF1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCGRK5-SUMF1chr10121191039ENST00000369108chr34110429ENST00000534863TCGA-DX-A48R-01A

Top

Potential target of CAR-T therapy development for GRK5-SUMF1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
GRK5chr10121191039ENST00000369108SUMF1chr34110429ENST00000534863
GRK5chr10121191039ENST00000392870SUMF1chr34110429ENST00000534863

Top

Related Drugs to GRK5-SUMF1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GRK5-SUMF1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource